首页 > 最新文献

Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose最新文献

英文 中文
Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. 基于结核杆菌感染风险的结核病流行病学最新研究。
I Sutherland

This review describes recent epidemiological studies, based upon the risk of infection with tubercle bacilli. In the Netherlands the risk of infection has been decreasing steeply and exponentially for many years, but in some developing countries there was little secular trend in the absence of intensive control measures. Variations in the risk of infection with age are being examined. A comprehensive statistical analysis has shown that the major risk of development of tuberculosis is following a recent primary infection; the risk is smaller following reinfection of a previously infected subject, and is very small indeed, in the absence of reinfection, if the primary infection took place more than 5 years previously.

这篇综述描述了最近基于结核杆菌感染风险的流行病学研究。在荷兰,感染风险多年来一直呈指数级急剧下降,但在一些发展中国家,由于缺乏强化控制措施,几乎没有长期趋势。正在研究感染风险随年龄的变化情况。一项全面的统计分析表明,发生结核病的主要危险发生在最近一次原发感染之后;先前感染的受试者再感染后的风险较小,如果初次感染发生在5年以上,在没有再感染的情况下,风险确实很小。
{"title":"Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli.","authors":"I Sutherland","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This review describes recent epidemiological studies, based upon the risk of infection with tubercle bacilli. In the Netherlands the risk of infection has been decreasing steeply and exponentially for many years, but in some developing countries there was little secular trend in the absence of intensive control measures. Variations in the risk of infection with age are being examined. A comprehensive statistical analysis has shown that the major risk of development of tuberculosis is following a recent primary infection; the risk is smaller following reinfection of a previously infected subject, and is very small indeed, in the absence of reinfection, if the primary infection took place more than 5 years previously.</p>","PeriodicalId":76883,"journal":{"name":"Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose","volume":"19 ","pages":"1-63"},"PeriodicalIF":0.0,"publicationDate":"1976-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12009817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BCG vaccination and epidemiological situation: a decision making approach to the use of BCG. 卡介苗接种与流行病学情况:卡介苗使用的决策方法。
A Rouillon, H Waaler

The clinical efficacy of a well-controlled and correctly applied BCG vaccine can hardly be questioned, nor its usefulness under individual circumstances. But a problem more and more often raised now is that of the opportuneness, at the present time, to still use BCG on a mass- systematic - scale, particularly in the TB control programmes of low-prevalence countries. The article proposes an approach which, alongside with other methods already presented for assessing the epidemiological value of BCG and its public health indications, can help appreciate the advantages and disadvantages brought by vaccination in high- as well as in low-prevalence countries. The article focuses on the future, i.e. on what can, from now on, be expected from BCG in terms of epidemiological, economical and psychological benefits. Test runs were made considering three cohorts of 100,000 individuals (newborn, school enterers, school leavers), vaccinated or not vaccinated, submitted to various risks of infection (corresponding to conditions of high-, intermediate- and low-prevalence of tuberculosis) and experiencing various breakdown rates from infection to disease. Cost for BCG on the one hand, and cost for diagnosis, treatment of tuberculosis and loss of wages on the other, were also entered in the calculations; an attempt was also made to quantify in absolute terms and in relative ones the in conveniences linked to the application of BCG itself. Beyond figures and results presented as examples, what is more important is that the article furnished a method of reasoning and the possibility to feed one's own data in the model; it may help to encompass the scope and implications of a decision, and it furnishes elements of dialogue with other members of the planning team. It should be well realized that the elements provided and those which can be worked out are elements of reflexion to found a decision; the decision itself - to start, to pursue or to stop BCG on a mass scale - is of political nature (public health policy): it always implies a value judgement - from the part of the providers of the services and/or, preferably, from the part of the users, i.e. a preference which is the result of a 'weighing' between advantages and inevitable disadvantages, both involving time, place, existing system, existing beliefs and other fields of health and welfare.

一种控制良好、正确使用的卡介苗的临床疗效不容置疑,它在个别情况下的有效性也不容置疑。但是,现在越来越经常提出的一个问题是,目前仍有机会大规模系统地使用卡介苗,特别是在低流行国家的结核病控制规划中。这篇文章提出了一种方法,与已经提出的用于评估卡介苗的流行病学价值及其公共卫生适应症的其他方法一起,可以帮助了解在高流行国家和低流行国家接种疫苗带来的利弊。本文着眼于未来,即从现在开始,BCG在流行病学、经济和心理效益方面的预期。试验考虑了3组10万人(新生儿、入学新生、离校生)、接种疫苗或未接种疫苗、面临各种感染风险(对应于结核病高、中、低流行状况)和经历从感染到疾病的各种分解率。BCG的费用、结核病的诊断、治疗费用和工资损失也被计算在内;还试图以绝对数字和相对数字来量化与BCG本身的应用有关的便利。除了作为例子的数字和结果之外,更重要的是,这篇文章提供了一种推理方法,并提供了在模型中输入自己数据的可能性;它可能有助于包含决策的范围和含义,并提供与规划团队其他成员对话的要素。应当充分认识到,所提供的要素和可以制定的要素是作出决定所需要考虑的要素;决定本身- -大规模地开始、继续或停止BCG - -具有政治性质(公共卫生政策):它总是意味着一种价值判断- -来自服务提供者和/或最好是来自使用者,即一种偏好,这是在优势和不可避免的劣势之间"权衡"的结果,涉及时间、地点、现有制度、现有信仰和其他卫生和福利领域。
{"title":"BCG vaccination and epidemiological situation: a decision making approach to the use of BCG.","authors":"A Rouillon,&nbsp;H Waaler","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The clinical efficacy of a well-controlled and correctly applied BCG vaccine can hardly be questioned, nor its usefulness under individual circumstances. But a problem more and more often raised now is that of the opportuneness, at the present time, to still use BCG on a mass- systematic - scale, particularly in the TB control programmes of low-prevalence countries. The article proposes an approach which, alongside with other methods already presented for assessing the epidemiological value of BCG and its public health indications, can help appreciate the advantages and disadvantages brought by vaccination in high- as well as in low-prevalence countries. The article focuses on the future, i.e. on what can, from now on, be expected from BCG in terms of epidemiological, economical and psychological benefits. Test runs were made considering three cohorts of 100,000 individuals (newborn, school enterers, school leavers), vaccinated or not vaccinated, submitted to various risks of infection (corresponding to conditions of high-, intermediate- and low-prevalence of tuberculosis) and experiencing various breakdown rates from infection to disease. Cost for BCG on the one hand, and cost for diagnosis, treatment of tuberculosis and loss of wages on the other, were also entered in the calculations; an attempt was also made to quantify in absolute terms and in relative ones the in conveniences linked to the application of BCG itself. Beyond figures and results presented as examples, what is more important is that the article furnished a method of reasoning and the possibility to feed one's own data in the model; it may help to encompass the scope and implications of a decision, and it furnishes elements of dialogue with other members of the planning team. It should be well realized that the elements provided and those which can be worked out are elements of reflexion to found a decision; the decision itself - to start, to pursue or to stop BCG on a mass scale - is of political nature (public health policy): it always implies a value judgement - from the part of the providers of the services and/or, preferably, from the part of the users, i.e. a preference which is the result of a 'weighing' between advantages and inevitable disadvantages, both involving time, place, existing system, existing beliefs and other fields of health and welfare.</p>","PeriodicalId":76883,"journal":{"name":"Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose","volume":"19 ","pages":"64-126"},"PeriodicalIF":0.0,"publicationDate":"1976-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12153765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1